Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Abstract 4773: AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL

Claudia Dall'Armi, Valentina Di Biasio, Chantal Paolini, Daniela Natale, Francesco Scalabrì, Antonino Missineo, Nadine Alaimo, Maurizio Nuzzo, Anna Demartis, Pamela Di Pasquale, Roberto Benoni, Fulvia Caretti, Elisa Beghetto, Fabrizio Colaceci, Romina Sasso, Vincenzo Pucci, Carlo Toniatti, Alessandro Carugo

Cancer Res (2025) 85 (8_Supplement_1): 4773.

https://doi.org/10.1158/1538-7445.AM2025-4773

Published: 21 April 2025

View articletitled, Abstract 4773: AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL

Journal Articles

Abstract 5614: Advancing treatment for brain tumors and metastases with brain permeable SHP2 inhibitor I-1000233

Francesca Puca, Alina Ciammaichella, Danilo Fabbrini, Martina Nibbio, Antonino Cucinotta, Giulio Auciello, Francesco Scalabrì, Christian Montalbetti, Alessia Petrocchi, Alessandro Carugo, Carlo Toniatti

Cancer Res (2025) 85 (8_Supplement_1): 5614.

https://doi.org/10.1158/1538-7445.AM2025-5614

Published: 21 April 2025

View articletitled, Abstract 5614: Advancing treatment for brain tumors and metastases with brain permeable SHP2 inhibitor I-1000233

Journal Articles

Abstract 1494: Clonal dominance defines metastatic dissemination in pancreatic cancer

Cancer Res (2024) 84 (6_Supplement): 1494.

https://doi.org/10.1158/1538-7445.AM2024-1494

Published: 22 March 2024

View articletitled, Abstract 1494: Clonal dominance defines metastatic dissemination in pancreatic cancer

Journal Articles

Abstract 4304: Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma

Cancer Res (2024) 84 (6_Supplement): 4304.

https://doi.org/10.1158/1538-7445.AM2024-4304

Published: 22 March 2024

View articletitled, Abstract 4304: Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma

Journal Articles

Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor

Francesca Puca, Danilo Fabbrini, Alina Ciammaichella, Antonino Missineo, Monica Bisbocci, Martina Nibbio, Annalise Di Marco, Claudia Apicella, Fabrizio Colaceci, Romina Sasso, Daniela Natale, Francesco Scalabrì, Cristina Alli, Vincenzo Pucci, Christian Montalbetti, Alessia Petrocchi, Alessandro Carugo, Carlo Toniatti

Cancer Res (2024) 84 (6_Supplement): 1975.

https://doi.org/10.1158/1538-7445.AM2024-1975

Published: 22 March 2024

View articletitled, Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor

Journal Articles

Abstract 1758: Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma

Cancer Res (2024) 84 (6_Supplement): 1758.

https://doi.org/10.1158/1538-7445.AM2024-1758

Published: 22 March 2024

View articletitled, Abstract 1758: Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma

Journal Articles

Abstract 2610: Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL

Cancer Res (2024) 84 (6_Supplement): 2610.

https://doi.org/10.1158/1538-7445.AM2024-2610

Published: 22 March 2024

View articletitled, Abstract 2610: Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL

Journal Articles

Abstract 92: Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples

Cancer Res (2023) 83 (7_Supplement): 92.

https://doi.org/10.1158/1538-7445.AM2023-92

Published: 04 April 2023

View articletitled, Abstract 92: Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples

Journal Articles

Abstract 94: Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma

Cancer Res (2023) 83 (7_Supplement): 94.

https://doi.org/10.1158/1538-7445.AM2023-94

Published: 04 April 2023

View articletitled, Abstract 94: Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma

Journal Articles

Abstract B022: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer

Federica Invrea, Alessandro Carugo, Consalvo Petti, Giulio Draetta, Enzo Medico

Cancer Res (2022) 82 (23_Supplement_1): B022.

https://doi.org/10.1158/1538-7445.CRC22-B022

Published: 01 December 2022

View articletitled, Abstract B022: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer

Journal Articles

Abstract LB079: Pancreatic clonal replica tumors display functional heterogeneity in response to KRAS pharmacological inhibition and reveal unique epigenetic vulnerabilities to overcome resistance

Hengyu Lyu, Rosalba Minelli, Charles E. Deckard, Sahil Seth, Justin Huang, Hong Jiang, Michael D. Peoples, Meggie Lam, Christopher A. Bristow, Daniel Gerlach, Ulrike Tontsch-Grunt, Chieh-Yuan Li, I-Lin Ho, Christopher P. Vellano, Marco H. Hofmann, Timothy P. Heffernan, Joseph R. Marszalek, Andrea Viale, Alessandro Carugo

Cancer Res (2022) 82 (12_Supplement): LB079.

https://doi.org/10.1158/1538-7445.AM2022-LB079

Published: 15 June 2022

View articletitled, Abstract LB079: Pancreatic clonal replica tumors display functional heterogeneity in response to KRAS pharmacological inhibition and reveal unique epigenetic vulnerabilities to overcome resistance

Journal Articles

Abstract 2611: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer

Federica Invrea, Alessandro Carugo, Sabrina Arena, Alberto Bardelli, Giulio F. Draetta, Enzo Medico

Cancer Res (2022) 82 (12_Supplement): 2611.

https://doi.org/10.1158/1538-7445.AM2022-2611

Published: 15 June 2022

View articletitled, Abstract 2611: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer

Journal Articles

Abstract 1327: Epithelial memory of resolved inflammation cooperates with oncogenic KRAS to limit tissue damage while promoting pancreatic cancer

I-Lin Ho, Edoardo Del Poggetto, Chiara Balestrieri, Er-Yen Yen, Francesca Citron, Rutvi Shah, Shaojun Zhang, Shan Jiang, Wantong Yao, Haoqiang Ying, Giannicola Genovese, Timothy Heffernan, Anirban Maitra, Linghua Wang, Timothy Wang, Giulio Draetta, Alessandro Carugo, Gioacchino Natoli, Andrea Viale

Cancer Res (2022) 82 (12_Supplement): 1327.

https://doi.org/10.1158/1538-7445.AM2022-1327

Published: 15 June 2022

View articletitled, Abstract 1327: Epithelial memory of resolved inflammation cooperates with oncogenic KRAS to limit tissue damage while promoting pancreatic cancer

Journal Articles

Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition

Liang Yan, Bo Tu, Jun Yao, Jing Gong, Alessandro Carugo, Christopher A. Bristow, Qiuyun Wang, Cihui Zhu, Bingbing Dai, Ya'an Kang, Leng Han, Ningping Feng, Yanqing Jin, Jason Fleming, Timothy P. Heffernan, Wantong Yao, Haoqiang Ying

Cancer Res (2021) 81 (15): 4054–4065.

https://doi.org/10.1158/0008-5472.CAN-20-3792

Published: 01 August 2021

View articletitled, Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition

Includes: Supplementary data

Journal Articles

Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models

Jing Han, Annette A. Machado, Mikhila Mahendra, Joseph R. Daniele, Christopher A. Bristow, Justin Kwang-Lay Huang, Alessandro Carugo, Robert A. Mullinax, Benjamin J. Bivona, Ningping Feng, Poojabahen Gandhi, Norbert Schweifer, Paolo Maria Chetta, Juan Manuel Garcia-Martinez, Frank Hilberg, Christopher P. Vellano, Timothy P. Heffernan, Joseph R. Marszalek

Cancer Res (2021) 81 (13_Supplement): 985.

https://doi.org/10.1158/1538-7445.AM2021-985

Published: 01 July 2021

View articletitled, Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models

Journal Articles

Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis

Cancer Res (2021) 81 (13_Supplement): 87.

https://doi.org/10.1158/1538-7445.AM2021-87

Published: 01 July 2021

View articletitled, Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis

Journal Articles

Abstract 2136: Diversity across the pancreatic ductal adenocarcinoma disease spectrum revealed by network-anchored functional genomics

Cancer Res (2021) 81 (13_Supplement): 2136.

https://doi.org/10.1158/1538-7445.AM2021-2136

Published: 01 July 2021

View articletitled, Abstract 2136: Diversity across the pancreatic ductal adenocarcinoma disease spectrum revealed by network-anchored functional genomics

Journal Articles

Abstract 1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors

Jeffrey J. Kovacs, Nakia D. Spencer, Christopher A. Bristow, Alessandro Carugo, Virginia Giluiani, Meredith A. Miller, Angela Harris, Ningping Feng, Michael L. Soth, Kang Le, Elisa de Stanchina, Charles M. Rudin, Giulio Draetta, Timothy A. Yap, Philip Jones, Timothy Heffernan

Cancer Res (2021) 81 (13_Supplement): 1102.

https://doi.org/10.1158/1538-7445.AM2021-1102

Published: 01 July 2021

View articletitled, Abstract 1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors

Journal Articles

Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress

Cancer Res (2021) 81 (2): 332–343.

https://doi.org/10.1158/0008-5472.CAN-19-3922

Published: 15 January 2021

View articletitled, Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress

Includes: Supplementary data

Journal Articles

Abstract 1935: The NEDD8 and EGFR pathways are independent therapeutic targets in colorectal cancer

Federica Invrea, Alessandro Carugo, Consalvo Petti, Cristopher Bristow, Michael Peoples, Carlotta Cancelliere, Alessia Corrado, Alberto Bardelli, Claudio Isella, Giulio F. Draetta, Enzo Medico

Cancer Res (2020) 80 (16_Supplement): 1935.

https://doi.org/10.1158/1538-7445.AM2020-1935

Published: 15 August 2020

View articletitled, Abstract 1935: The NEDD8 and EGFR pathways are independent therapeutic targets in colorectal cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4773: AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL

Abstract 5614: Advancing treatment for brain tumors and metastases with brain permeable SHP2 inhibitor I-1000233

Abstract 1494: Clonal dominance defines metastatic dissemination in pancreatic cancer

Abstract 4304: Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma

Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor

Abstract 1758: Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma

Abstract 2610: Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL

Abstract 92: Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples

Abstract 94: Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma

Abstract B022: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer

Abstract LB079: Pancreatic clonal replica tumors display functional heterogeneity in response to KRAS pharmacological inhibition and reveal unique epigenetic vulnerabilities to overcome resistance

Abstract 2611: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer

Abstract 1327: Epithelial memory of resolved inflammation cooperates with oncogenic KRAS to limit tissue damage while promoting pancreatic cancer

Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition

Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models

Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis

Abstract 2136: Diversity across the pancreatic ductal adenocarcinoma disease spectrum revealed by network-anchored functional genomics

Abstract 1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors

Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress

Abstract 1935: The NEDD8 and EGFR pathways are independent therapeutic targets in colorectal cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only